Ensign Peak Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $21.5M | Sell |
|
|||||
|
2025
Q1 | $21.5M | Buy |
|
|||||
|
2024
Q4 | $23.7M | Sell |
|
|||||
|
2024
Q3 | $20.1M | Sell |
|
|||||
|
2024
Q2 | $37.5M | Buy |
|
|||||
|
2024
Q1 | $21.3M | Buy |
|
|||||
|
2023
Q4 | $9.57M | Sell |
|
|||||
|
2023
Q3 | $9.59M | Sell |
|
|||||
|
2023
Q2 | $9.04M | Buy |
|
|||||
|
2023
Q1 | $6.93M | Buy |
|
|||||
|
2022
Q4 | $6.25M | Buy |
|
|||||
|
2022
Q3 | $4.72M | Sell |
|
|||||
|
2022
Q2 | $5.99M | Sell |
|
|||||
|
2022
Q1 | $6.19M | Sell |
|
|||||
|
2021
Q4 | $6.12M | Sell |
|
|||||
|
2021
Q3 | $10.3M | Sell |
|
|||||
|
2021
Q2 | $10.6M | Buy |
|
|||||
|
2021
Q1 | $4.74M | Sell |
|
|||||
|
2020
Q4 | $16.7M | Sell |
|
|||||
|
2020
Q3 | $20M | Buy |
|
|||||
|
2020
Q2 | $16.1M | Buy |
|
|||||
|
2020
Q1 | $8.04M | Sell |
|
|||||
|
2019
Q4 | $11.9M | Buy |
|